Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01767155 · ClinicalTrials.gov registry record · Phase 3
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
A Phase 3 study of Endometrial Cancer, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 3
- Development phase
- 511
- Enrollment target
- 20
- Study locations
NCT01767155 is a Phase 3 study of Endometrial Cancer that has completed, run by AEterna Zentaris. The registered enrollment target is 511 participants, roughly in line with the 521-participant average among 181 other Endometrial Cancer trials with a reported enrollment target. The trial reports 20 study locations across 16 states.
The verdict
NCT01767155, a Phase 3 study of Endometrial Cancer, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 511 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.
Conditions Studied
Interventions
- DRUG doxorubicin
- DRUG AEZS-108 / zoptarelin doxorubicin
Study Locations (20)
California
- USC Norris Hospital and LAC+USC Medical Center - Los Angeles
- University of California, Irvine - Medical Center - Orange
Connecticut
- Hartford Hospital - Hartford
- The Hospital of Central Connecticut - New Britain
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
North Carolina
- Hope Women's Cancer Centers / Mission Hospital, Inc. - Asheville
- Levine Cancer Institute - Charlotte
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Colorado
- University of Colorado - Aurora
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01767155
The ClinicalTrials.gov registry entry for NCT01767155 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 511 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 521-participant average among 181 other Endometrial Cancer trials with a reported enrollment target. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which doxorubicin is the first listed.
NCT01767155 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01767155 about?
NCT01767155 is a clinical study titled "Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer". Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.
What is the current status of trial NCT01767155?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 511 participants. The study started on 2013-04. Estimated completion is 2017-01-30.
What conditions does trial NCT01767155 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT01767155?
The interventions under investigation include: doxorubicin (DRUG), AEZS-108 / zoptarelin doxorubicin (DRUG).
Who is sponsoring clinical trial NCT01767155?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01767155 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.